| Naslov: | SGLT2i for evidence based cardiorenal protection in diabetic and non-diabetic chronic kidney disease : a comprehensive review by EURECA-m and ERBP working groups of ERA |
|---|
| Avtorji: | ID Mark, Patrick B. (Avtor)
ID Sarafidis, Pantelis (Avtor)
ID Ekart, Robert (Avtor)
ID Ferro, Charles J. (Avtor)
ID Balafa, Olga (Avtor)
ID Fernandez-Fernandez, Beatriz (Avtor)
ID Herrington, William G. (Avtor)
ID Rossignol, Patrick (Avtor)
ID Del Vecchio, Lucia (Avtor)
ID Valdivielso, Jose M. (Avtor) |
|---|
| Datoteke: |  Mark-2023-SGLT2i_for_evidence-based_cardiorena.pdf (1,05 MB)
MD5: EF111EB4B346D1C36983E41A12B96796
 https://doi.org/10.1093/ndt/gfad112
|
|---|
| Jezik: | Angleški jezik |
|---|
| Vrsta gradiva: | Znanstveno delo |
|---|
| Tipologija: | 1.02 - Pregledni znanstveni članek |
|---|
| Organizacija: | MF - Medicinska fakulteta
|
|---|
| Opis: | Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850 million people globally. The leading causes of CKD is diabetes and hypertension, which together account for >50% of patients with end-stage kidney disease. Progressive CKD leads to the requirement for kidney replacement therapy with transplantation or dialysis. In addition, CKD, is a risk factor for premature cardiovascular disease, particularly from structural heart disease and heart failure (HF). Until 2015, the mainstay of treatment to slow progression of both diabetic and many non-diabetic kidney diseases was blood pressure control and renin-angiotensin system inhibition; however, neither angiotensin-converting enzyme inhibitors (ACEIs) nor angiotensin receptor blockers (ARBs) reduced cardiovascular events and mortality in major trials in CKD. The emergence of cardiovascular and renal benefits observed with sodium-glucose cotransporter-2 inhibitors (SGLT2i) from clinical trials of their use as anti-hyperglycaemic agents has led to a revolution in cardiorenal protection for patients with diabetes. Subsequent clinical trials, notably DAPA-HF, EMPEROR, CREDENCE, DAPA-CKD and EMPA-KIDNEY have demonstrated their benefits in reducing risk of HF and progression to kidney failure in patients with HF and/or CKD. The cardiorenal benefits—on a relative scale—appear similar in patients with or without diabetes. Specialty societies’ guidelines are continually adapting as trial data emerges to support increasingly wide use of SGLT2i. This consensus paper from EURECA-m and ERBP highlights the latest evidence and summarizes the guidelines for use of SGLT2i for cardiorenal protection focusing on benefits observed relevant to people with CKD. |
|---|
| Ključne besede: | cardiorenal syndrome, cardiovascular, chronic renal failure, diabetic kidney disease, heart failure |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Datum objave: | 25.05.2023 |
|---|
| Založnik: | Oxford University Press |
|---|
| Leto izida: | 2023 |
|---|
| Št. strani: | Str. 2444-2455 |
|---|
| Številčenje: | Letn. 38, Št. 11 |
|---|
| PID: | 20.500.12556/DKUM-86979  |
|---|
| UDK: | 616.6 |
|---|
| COBISS.SI-ID: | 155795971 |
|---|
| DOI: | 10.1093/ndt/gfad112 |
|---|
| ISSN pri članku: | 1460-2385 |
|---|
| Datum objave v DKUM: | 21.02.2024 |
|---|
| Število ogledov: | 374 |
|---|
| Število prenosov: | 32 |
|---|
| Metapodatki: |    |
|---|
| Področja: | Ostalo
|
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Skupna ocena: | (0 glasov) |
|---|
| Vaša ocena: | Ocenjevanje je dovoljeno samo prijavljenim uporabnikom. |
|---|
| Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
